The pharmacy behind your vial, and the register that will not tell you about it
Somebody is making the thing you are injecting, and it is almost never the company that sold it to you. There are two kinds of compounder in federal law with two different sets of obligations, and only one of them appears on a public FDA register. We read that register end to end on September 8, 2026: 96 facilities, of which 40 have never been inspected and 53 were issued a Form 483 at their last inspection.
What this comes down to
- A 503B outsourcing facility registers with the FDA, appears on a public list, and is subject to current good manufacturing practice requirements. A 503A pharmacy is state-licensed, appears on no federal list, and is not.
- The FDA's register held 96 facilities on its stated update date. Forty of them carry Not yet inspected in the inspection column.
- Fifty-three of the 96 show a Form 483 issued at their last inspection, and 32 show an action status of Open. Ninety of the 96 state that they intend to compound sterile drugs from bulk substances.
- The absence of a company from that list proves nothing about its pharmacy, because most compounding pharmacies are 503A and are not on it. The list is a starting point, not a verdict.
Two kinds of compounder, and only one public list
The distinction that matters is a single sentence in the FDA's own questions and answers: drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements, and drugs compounded by a licensed pharmacist in a state-licensed pharmacy under section 503A are not[2]. That is the whole difference in obligations. The outsourcing facility category, and the registration requirement that puts a facility on a public list at all, come from their own section of the statute[3]. A 503A pharmacy answers to its state board instead, and appears on no federal register.
No compounded drug is FDA-approved, whichever kind of facility made it. Approval is a judgment about a specific product's safety, effectiveness and manufacturing, and it produces a reviewed label with indications, dosing, warnings and trial-derived adverse reaction rates[4]. Compounding law is a set of conditions under which a drug may be made without any of that. A 503B facility making an unapproved preparation is following manufacturing rules, not producing an approved medicine.
What the public register actually shows
The FDA publishes a table of facilities registered as human drug compounding outsourcing facilities under section 503B, with the columns that matter printed next to each name: initial registration date, most recent registration date, last inspection, whether a Form 483 was issued, whether a recall was conducted, and the action based on the last inspection[1]. The page we read carried the line Updated as of 9/8/2026 on its face, which is the date recorded here rather than anything in the URL.
FDA registered outsourcing facilities table, parsed from the page HTML
every table row on the page, classified on the Last Inspection and Form 483 columns; a row counts as never inspected when its inspection cell reads Not yet inspected
Returned 40. Positive control — rows whose Last Inspection column names an actual date — returned 56 through the identical filter in the same session.
Ninety-six facility rows in total. Forty read Not yet inspected and 56 carry a date, which is the control: a parser that had stopped reading the table would return zero for both, and it does not. The Form 483 column is spelled two ways in the source — 49 rows read Yes and 4 read 483 — so the 53 figure elsewhere on this page is those two added together, which is why it is not 49. Forty-one rows read N/A in that column, and every one of those is a facility that has never been inspected.
Read the action column and 32 rows show Open, alongside a handful of regulatory meetings held, an untitled letter and a warning letter closeout. Ninety of the 96 state that they intend to compound sterile drugs from bulk substances, which is the category of activity the sterility failures in this market have historically come from. None of that is a scandal; a register that shows inspections, observations and open actions is a register doing its job. What it is not is a badge.
What you can actually check, in about ten minutes
- Ask the seller, in writing, for the name and the state of the pharmacy that will dispense your prescription. A company that will not name it has answered the question.
- Search that name against the FDA's outsourcing facility register. A hit tells you the facility is a 503B and shows you its inspection history. A miss tells you only that it is not a 503B.
- If it is not on that list, look it up on the state board of pharmacy website for the state it is licensed in. That is where a 503A pharmacy's license and discipline record lives.
- Ask what the beyond-use date on your vial is and what it is based on. Storage and beyond-use dating on a compounded GLP-1 covers what those dates mean and how rarely they are published.
- Ask what the certificate of analysis covers and who issued it. What third-party testing proves is the article about how little a certificate on a marketing page establishes.
On our own roster, all 257 sellers we have read carry a published review, and the pharmacy question is one we ask in every one of them. Where a company names its pharmacy we record it; where it does not, that absence is in the review too. It is the same question underneath the men's-hormone market, where the most commonly sold molecule has no approved product at all — the telehealth testosterone rules set out why. The same discipline runs through how we grade and how we verify prices: what a company will not tell you is a finding, not a gap in our research.
Questions people actually ask
What is the difference between a 503A and a 503B pharmacy?
A 503B outsourcing facility registers with the FDA, appears on a public register and is subject to current good manufacturing practice requirements. A 503A pharmacy is licensed by its state, appears on no federal list, and is not subject to those requirements.
How do I check whether a compounding pharmacy is registered with the FDA?
Search the FDA's published table of facilities registered as outsourcing facilities under section 503B. It lists each facility by name and location with its registration dates, last inspection, whether a Form 483 was issued and what action followed.
Does being on the FDA list mean a pharmacy is safe?
No. On the version of the list we read, 40 of 96 facilities had never been inspected and 53 had a Form 483 issued at their last inspection. The register is a record of registration and inspection history, not an endorsement.
My pharmacy is not on the list. Is that bad?
Not by itself. Most compounding pharmacies operate under section 503A and are licensed by a state board rather than registered with the FDA, so they never appear on that list. The place to check them is the state board of pharmacy for the state they are licensed in.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.Facilities Registered as Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. U.S. Food and Drug Administration, 2026. Source · Document dated September 2026The table's own line reads Updated as of 9/8/2026. Parsed on 2026-09-12 it carried 96 facility rows with the columns Facility, Contact, Initial Registration Date, Most Recent Registration Date, Last Inspection, Form 483 Issued?, Recall Conducted?, Action Based on Last Inspection, and Intends to Compound Sterile Drugs From Bulk Substances. Forty rows read Not yet inspected; 49 read Yes and 4 read 483 in the Form 483 column, 41 read N/A; 32 rows read Open in the action column; 90 rows read Yes in the sterile-from-bulk column. Fetched at HTTP 200 and 69,904 bytes against a nonsense path on the same host returning HTTP 404 at 14,497 bytes in the same session.
- 2.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements; drugs compounded by a licensed pharmacist in a state-licensed pharmacy under section 503A are not. The page's own line reads Content current as of: 09/16/2025, and it was fetched at HTTP 200 and 42,967 bytes.
- 3.21 U.S.C. 353b — Outsourcing facilities. Office of the Law Revision Counsel, United States Code, 2026. Source · Document dated September 2026The section that creates the outsourcing facility category, sets the conditions under which a drug compounded in one is exempt from certain requirements, and requires registration with the Secretary. Fetched at HTTP 200 and 171,383 bytes against a nonsense section number returning HTTP 302 with an empty body in the same session.
- 4.WEGOVY (semaglutide) injection and tablets — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated June 2026The comparison this article rests on: an approved product carries FDA-reviewed labeling with indications, dosing, warnings and trial-derived adverse reaction rates. A compounded preparation carries none of that, whichever kind of facility made it.
Key figures